Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Study sponsor: OPKO Health, Inc. · OPK
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2019-08Actual
Enrollment · participants224Actual
Source updated2025-07-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.